PGP and lymphoid neoplasm: All three generations were shown to inhibit P-gp function in many tumor cells in vitro, including lymphoid tumors, and some adverse effects observed with the first- and second-generation agents, such as the inhibition of cytochrome P450 3A, were decreased in the third-generation inhibitors [101].